natgillin/translations-raw huggingface dataset:
Co-administration of potent P-glycoprotein inhibitors such as cyclosporine, ketoconazole, erythromycin, clarithromycin, verapamil, dronedarone and amiodarone is not recommended (see sections 4.5 and 5.2).
Sočasno dajanje močnih P-glikoproteinskih inhibitorjev, kot so ciklosporin, ketokonazol, eritromicin, klaritromicin, verapamil, dronedaron in amiodaron, ni priporočljivo (glejte poglavji 4.5 in 5.2).
Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.
Sočasna uporaba pregabalina s peroralnima kontraceptivoma noretisteronom in/ali etinilestradiolom ne vpliva na farmakokinetiko nobene od teh učinkovin v stanju dinamičnega ravnovesja.
co-administration of PREZISTA
PREZISTA skupaj z majhnim
co-administration of PREZISTA
Pri uporabi zdravila PREZISTA
co-administration of PREZISTA
zdravila PREZISTA z majhnim
Co-administration of proton- pump inhibitors had no relevant impact on edoxaban exposure.
Sočasno dajanje inhibitorjev protonske črpalke ni pomembno vplivalo na izpostavljenost edoksabanu.
Co-administration of raloxifene or hormone replacement therapy with FORSTEO did not alter the effects of FORSTEO on serum or urine calcium or on clinical adverse events.
Sočasno dajanje zdravila FORSTEO in raloksifena ali hormonske nadomestne terapije z zdravilom FORSTEO ni spremenilo učinkov zdravila FORSTEO na serumske koncentracije kalcija, koncentracije kalcija v seču ali na klinične neželene dogodke.
Co-administration of REYATAZ and indinavir is not recommended (see section 4.4).
Sočasne uporabe zdravila REYATAZ in indinavirja ne priporočamo (glejte poglavje 4.4).
Co-administration of rifampicin (an inhibitor of Organic Anion Transporting Polypeptide [OATP], a strong inducer of CYP3A and 2C19, and inducer of P-gp and uridine-diphospho- glucuronosyltransferases [UGTs]) was associated with a transient (approximately 2-fold) increase in ambrisentan exposure following initial doses in healthy volunteers.
Sočasna uporaba rifampicina ( zaviralec transportnega polipeptida organskih anionov [OATP], močan induktor CYP3A in 2C19 ter induktor P-gp in uridin-difosfo-glukuronoziltransferaz [UGT]) je bila pri zdravih prostovoljcih povezana s prehodnim (približno 2-kratnim) povečanjem izpostavljenosti ambrisentanu po prvih odmerkih.
Co-administration of rifampicin (an inhibitor of Organic Anion Transporting Polypeptide [OATP], a strong inducer of CYP3A and 2C19, and inducer of P-gp and uridine-diphospho- glucuronosyltransferases [UGTs]) was associated with a transient (approximately 2-fold) increase in ambrisentan exposure following initial doses in healthy volunteers.
Sočasna uporaba rifampicina (zaviralec transportnega polipeptida organskih anionov[OATP], močan induktor CYP3A in 2C19 ter induktor P-gp in uridin-difosfo-glukuronoziltransferaz [UGT]) je bila pri zdravih prostovoljcih povezana s prehodnim (približno 2-kratnim) povečanjem izpostavljenosti ambrisentanu po prvih odmerkih.
Co-administration of rifampicin with telaprevir
Sočasna uporaba rifampicina s telaprevirjem
Co-administration of rifampicin, rifabutin, and rifapentine, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Sočasno dajanje rifampicina, rifabutina in rifapentina, ki so induktorji P-gp, lahko zmanjša koncentracije alafenamidtenofovirata v plazmi, kar ima lahko za posledico izgubo terapevtskega učinka in razvoj rezistence.
Co-administration of rilpivirine and medicinal products that inhibit CYP3A has been observed to increase the plasma concentrations of rilpivirine.
Pri sočasni uporabi rilpivirina z učinkovinami, ki zavirajo CYP3A, so opazili povečanje koncentracije rilpivirina v plazmi.
Co-administration of ritonavir and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse effects.
Sočasna uporaba ritonavirja z zdravili, ki se primarno presnavljajo s CYP3A, lahko poveča koncentracijo drugega zdravila v plazmi, to pa lahko poveča ali podaljša njegove terapevtske in neželene učinke.
Co-administration of ritonavir with fosamprenavir increase plasma amprenavir AUC by approximately 2-fold and plasma C,ss by 4- to 6-fold, compared to values obtained when fosamprenavir is administered alone.
V primerjavi z uporabo fosamprenavirja samega se pri uporabi ritonavirja skupaj s fosamprenavirjem plazemska AUC amprenavirja poveča za približno 2-krat, plazemska C,ss pa za 4- do 6-krat.
Co-administration of rivaroxaban
Pri uporabi afatiniba z zdravilom
Co-administration of rivaroxaban
Sočasna uporaba rivaroksabana in
Co-administration of rivaroxaban and Tybost is not recommended.
Sočasna uporaba rivaroksabana in zdravila Tybost se ne priporoča.
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50 % decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects.
Sočasna uporaba rivaroksabana in rifampicina, ki je močan induktor CYP3A4, zmanjša povprečno AUC rivaroksabana za približno 50 %, hkrati zmanjša njegove farmakodinamične učinke.
Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax, but slightly lower values for Cmax (832 ng/ml) and AUC (782 ng·h/ml).
Vnos nearomatiziranih tablet robenakoksiba s hrano ni povzročil nobenih sprememb pri Tmax (0,5 h), pač pa malo nižjo koncentracijo Cmax (832 ng/ml) in AUC (782 ng·h/ml).
Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h), Cmax (1,201 ng/ml) or AUC (1383 ng·h/ml).
Vnos tablet robenakoksiba s tretjino dnevnega obroka hrane ni povzročil bistvenih sprememb pri Tmax (0,5 h), Cmax (1201 ng/ml) ali AUC (1383 ng·h/ml).
Co-administration of robenacoxib tablets with the entire daily food ration produced no delay in Tmax (0.5 h), but a lower Cmax (691 ng/ml) and a slightly lower AUC (1,069 ng·h/ml).
Pri vnosu tablet robenakoksiba s celotnim dnevnim obrokom hrane sta bili, ob hitri absorbciji (Tmax 0,5 h), maksimalna koncentracija Cmax (691 ng/ml) in površina AUC (1069 ng·h/ml) rahlo nižji.
Co-administration of salmeterol and Tybost is not recommended (see section 4.4).
Sočasno dajanje zdravila Tybost in salmeterola se ne priporoča (glejte poglavje 4.4).
Co-administration of salmeterol with REYATAZ/ritonavir is not recommended (see section 4.4).
Sočasna uporaba salmeterola in zdravila REYATAZ/ritonavirja ni priporočljiva (glejte poglavje 4.4).
Co-administration of Samsca with other treatments for hyponatraemia, and medications that increase serum sodium concentration, is not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations (see section 4.5).
Sočasna uporaba zdravila Samsca z drugimi oblikami zdravljenja hiponatriemije ali drugimi zdravili, ki povečujejo koncentracije natrija v serumu, ni priporočljiva med začetnim zdravljenjem ali za druge bolnike z zelo nizko koncentracijo natrija v serumu ob izhodišču (glejte poglavje 4.5).
Co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre- existing liver disease.
Sočasno dajanje sakvinavirja in ritonavirja je vodilo v resne neželene dogodke, predvsem v diabetično ketoacidozo in motnje jetrnega delovanja, še posebno pri bolnikih s prej obstoječim obolenjem jeter.
Co-administration of saquinavir/ritonavir and Atripla is not recommended.
uporabo efavirenza in majhnih
Co-administration of Senshio with fluconazole
Sočasna uporaba zdravila Senshio s flukonazolom
Co-administration of Senshio with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known, or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.
Sočasni uporabi zdravila Senshio z močnimi/zmernimi zaviralci CYP3A4 se je treba izogniti pri bolnicah, za katere je znano ali pri katerih obstaja sum, da imajo slabo presnovo s CYP2C9 na podlagi genotipizacije ali predhodne anamneze/izkušenj z drugimi substrati CYP2C9.
Co-administration of simeprevir with efavirenz is not recommended.
Priporočilo glede sočasne uporabe z efavirenzem
Co-administration of simvastatin or lovastatin with REYATAZ is contraindicated due to an increased risk of myopathy including rhabdomyolysis. (see section 4.3).
Sočasna uporaba simvastatina ali lovastatina z zdravilom REYATAZ je kontraindicirana zaradi večjega tveganja za pojav miopatije, vključno z rabdomiolizo (glejte poglavje 4.3).
Co-administration of single or multiple doses of dexamethasone (40 mg/ day) has no clinically relevant effect on the multiple dose pharmacokinetics of lenalidomide (25 mg/ day).
Sočasna uporaba z enkratnimi ali večkratnimi odmerki deksametazona (40 mg/dan) ni klinično pomembno vplivala na farmakokinetiko večkratnih odmerkov lenalidomida (25 mg/dan).
Co-administration of sirolimus (2 mg single dose) with multiple-dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 100 mg every 12 hours for 8 days) in healthy subjects has been reported to increase sirolimus Cmax and AUC by an average of 7-fold and 11-fold respectively.
Sočasna uporaba sirolimusa (2 mg v enkratnem odmerku) z večkratnimi, peroralnimi odmerki vorikonazola (1 dan 400 mg na 12 ur, nato 8 dni 100 mg na 12 ur) je pri zdravih osebah povzročila zvečanje Cmax in AUC sirolimusa v poprečju za 7 oziroma 11-krat.
Co-administration of sirolimus (2 mg single dose) with multiple-dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 100 mg every 12 hours for 8 days) in healthy subjects has been reported to increase sirolimus Cmax and AUC by an average of 7-fold and 11-fold, respectively.
Sočasna uporaba sirolimusa (2 mg v enkratnem odmerku) z večkratnimi, peroralnimi odmerki vorikonazola (1 dan 400 mg na 12 ur, nato 8 dni 100 mg na 12 ur) je pri zdravih osebah povzročila zvečanje Cmax in AUC sirolimusa v poprečju za 7 oziroma 11-krat.
Co-administration of sirolimus and ketoconazole is not recommended (see section 4.4).
Sočasna uporaba sirolimusa in ketokonazola ni priporočena (glejte poglavje 4.4).
Co-administration of sirolimus and rifampicin is not recommended (see section 4.4).
Sočasna uporaba sirolimusa in rifampicina ni priporočena (glejte poglavje 4.4).
Co-administration of sirolimus and voriconazole is not recommended (see section 4.4).
Sočasna uporaba sirolimusa in vorikonazola ni priporočena (glejte poglavje 4.4).
Co-administration of sirolimus with strong inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin, rifabutin) is not recommended (see section 4.5).
Sočasno zdravljenje s sirolimusom in močnimi zaviralci CYP3A4 (na primer ketokonazolom, vorikonazolom, itrakonazolom, telitromicinom ali klaritromicinom) ali induktorji CYP3A4 (na primer rifampinom, rifabutinom) ni priporočljivo (glejte poglavje 4.5).
Co-administration of Sonata together with inducers of CYP3A4 such as rifampicin, carbamazepine and phenobarbitone, may result in a reduction of zaleplon’s efficacy.
Sočasno dajanje zdravila Sonata skupaj z induktorji CYP3A4, kot so rifampicin, karbamazepin in fenobarbiton, lahko povzroči zmanjšanje učinkovitosti zaleplona.
Co-administration of Sonata with a single 800 mg dose of erythromycin, a strong, selective CYP3A4 inhibitor, produced a 34% increase in zaleplon’s plasma concentrations.
Sočasna uporaba zdravila Sonata z enkratnim 800 mg odmerkom eritromicina, močnega, selektivnega zaviralca CYP3A4, je povzročila 34% povečanje koncentracije zaleplona v plazmi.
Co-administration of Sonata with medicinal products known to influence CYP3A4 is expected to result in changes in zaleplon’s plasma concentrations. (See section 4.5).
Sočasno odmerjanje zdravila Sonata z zdravili, ki vplivajo na izoencim CYP3A4, lahko povzroči spremembe koncentracije zaleplona v plazmi (glejte poglavje 4.5).
Co-administration of Sovaldi with modafinil is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of Sovaldi.
Pričakuje se, da bo sočasno dajanje zdravila Sovaldi z modafinilom zmanjšalo koncentracije sofosbuvirja, kar bo povzročilo zmanjšan terapevtski učinek zdravila Sovaldi.
Co-administration of Sovaldi with oxcarbazepine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of Sovaldi.
Pričakuje se, da bo sočasno dajanje zdravila Sovaldi z okskarbazepinom zmanjšalo koncentracije sofosbuvirja, kar bo povzročilo zmanjšan terapevtski učinek zdravila Sovaldi.
Co-administration of Sovaldi with rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of Sovaldi.
Pričakuje se, da bo sočasno dajanje zdravila Sovaldi z rifapentinom zmanjšalo koncentracije sofosbuvirja, kar bo povzročilo zmanjšan terapevtski učinek zdravila Sovaldi.
Co-administration of St. John’s wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Sočasno dajanje šentjanževke, ki je induktor P-gp, lahko zmanjša koncentracije alafenamidtenofovirata v plazmi, kar ima lahko za posledico izgubo terapevtskega učinka in razvoj rezistence.
Co-administration of Stribild and other medicinal products primarily metabolised by CYP3A such as amiodarone, quinidine, cisapride, pimozide, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see section 4.3).
Sočasna uporaba zdravila Stribild in drugih zdravil, ki jih pretežno presnavlja CYP3A, kot so amiodaron, kvinidin, cisaprid, pimozid, alfuzosin in sildenafil za pljučno arterijsko hipertenzijo, je kontraindicirana (glejte poglavje 4.3).
Co-administration of Stribild and some medicinal products that induce CYP3A such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Sočasno dajanje zdravila Stribild in nekaterih zdravil, ki inducirajo CYP3A, kot so šentjanževka (Hypericum perforatum), rifampicin, karbamazepin, fenobarbital in fenitoin lahko povzroči značilno zmanjšanje koncentracij kobicistata in elvitegravirja v plazmi, kar ima lahko za posledico izgubo terapevtskega učinka in razvoj rezistence (glejte poglavje 4.3).
Co-administration of Stribild with oral contraceptives containing progestagens other than norgestimate has not been studied and therefore should be avoided.
Sočasne uporabe zdravila Stribild s peroralnimi kontraceptivi, ki vsebujejo druge progestagene kot norgestimat, niso preučili, zato se ji je treba izogniti.
Co-administration of Stribild with oral contraceptives containing progestagens other than norgestimate has not been studied and, therefore, should be avoided.
Sočasne uporabe zdravila Stribild s peroralnimi kontraceptivi, ki vsebujejo druge progestagene kot norgestimat, niso preučili, zato se ji je treba izogniti.
Co-administration of strong CYP3A4 inducers such as carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, and St. John’s Wort with ponatinib should be avoided, and alternatives to the CYP3A4 inducer should be sought, unless the benefit outweighs the possible risk of ponatinib underexposure.
Sočasni uporabi močnih induktorjev CYP3A4, kot so karbamazepin, fenobarbital, fenitoin, rifabutin, rifampicin in šentjanževka s ponatinibom, se je treba izogniti in poiskati alternative induktorju CYP3A4, razen če so koristi večje od možnega tveganja za premajhno izpostavljenost ponatinibu.
Co-administration of strong CYP3A4/2C9-inhibitors to CYP2D6 poor metabolisers could potentially result in higher exposure (see section 4.5).
Sočasna uporaba močnih inhibitorjev CYP3A4/2C9 pri bolnikih z upočasnjeno presnovo s CYP2D6 lahko potencialno povzroči višjo izpostavljenost (glejte poglavje 4.5).
Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast.
Sočasno dajanje močnega spodbujevalca encima citokromom P450 3A4 (CYP3A4), rifampicina, je povzročilo zmanjšanje sistemske izpostavljenosti apremilastu, kar lahko povzroči izgubo njegove učinkovitosti.
Co-administration of tadalafil for
Pri sočasni uporabi zaviralcev
Co-administration of TELZIR/ritonavir with alfuzosin is contraindicated (see section 4.3)
Sočasna uporaba zdravila TELZIR/ritonavir z alfuzosinom je kontraindicirana (glejte poglavje 4.3).
Co-administration of temsirolimus 5 mg with ketoconazole, a potent CYP3A4 inhibitor, had no significant effect on temsirolimus Cmax or AUC; however, sirolimus AUC increased 3.1-fold, and AUCsum (temsirolimus + sirolimus) increased 2.3-fold compared to temsirolimus alone.
Sočasna uporaba temsirolimusa v odmerku 5 mg s ketokonazolom, ki je močan zaviralec CYP3A4, ni pomembno vplivala na Cmax ali AUC temsirolimusa; vendar pa se je AUC sirolimusa zvečala za 3,1- krat, AUCvsota (temsirolimus + sirolimus) pa se je zvečala za 2,3-krat v primerjavi s temsirolimusom samim.
Co-administration of temsirolimus with rifampicin, a potent CYP3A4/5 inducer, had no significant effect on temsirolimus maximum concentration (Cmax) and area under the concentration vs. time curve (AUC)after intravenous administration, but decreased sirolimus Cmax by 65% and AUC by 56%, compared to temsirolimus treatment alone.
Sočasna intravenska uporaba temsirolimusa z rifampicinom, ki je močan induktor CYP3A4/5, ni pomembno vplivala na maksimalno koncentracijo (Cmax) in površino pod krivuljo koncentracije v odvisnosti od časa (AUC) temsirolimusa, je pa v primerjavi z zdravljenjem samo s temsirolimusom zmanjšala Cmax sirolimusa za 65 % in AUC za 56 %.
Co-administration of tenofovir
Pri sočasni uporabi
Co-administration of tenofovir disoproxil and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za 40-60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina pri odmerku 400 mg dnevno je bila povezana s pomembnim zmanjšanjem števila celic CD4, morda zaradi znotrajceličnih interakcij, ki so povečale količino fosforiliranega (to je aktivnega) didanozina.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina pri odmerku 400 mg na dan je bila povezana s pomembnim zmanjšanjem števila celic CD4, morda zaradi znotrajcelične interakcije, ki je povečala količino fosforiliranega (to je aktivnega) didanozina.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina pri odmerku 400 mg na dan je bila povezana s pomembnim zmanjšanjem števila celic CD4, morda zaradi znotrajceličnih interakcij, ki so povečale količino fosforiliranega (to je aktivnega) didanozina.
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4 and Table 1).
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočena (glejte poglavje 4.4 in preglednico 1).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4 and Table 2).
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočena (glejte poglavje 4.4 in preglednico 2).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended (see section 4.4).
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočena (glejte poglavje 4.4).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočljiva, saj povzroča povečanje sistemske izpostavljenosti didanozinu za 40–60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Co-administration of tenofovir disoproxil fumarate and didanosine is not recommended.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina ni priporočena.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za 40-60%, kar lahko poveča tveganje pojava neželenih učinkov, povezanih z didanozinom.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za 40-60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina povzroča povečanje sistemske izpostavljenosti didanozinu za 40-60%, kar lahko poveča tveganje za pojav neželenih učinkov, povezanih z didanozinom (glejte poglavje 4.5).
Co-administration of tenofovir disoproxil fumarate and didanosine:
Sočasna uporaba dizoproksiltenofovirijevega fumarata in didanozina:
Co-administration of tenofovir disoproxil fumarate with cobicistat is expected to increase tenofovir plasma concentration.
Pričakuje se, da bo sočasna uporaba dizoproksiltenofovirat fumarata s kobicistatom zvišala koncentracije tenofovirja v plazmi.
Co-administration of tenofovir disoproxil fumarate with ledipasvir/sofosbuvir has been shown to increase plasma concentrations of tenofovir, especially when used together with an HIV regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer (ritonavir or cobicistat).
Sočasna uporaba dizoproksiltenofovirijevega fumarata z ledipasvirjem/sofobusvirjem poveča kocentracije tenofovirja v plazmi, še posebej, če se uporablja skupaj s zdravljenjem HIV, ki vključuje dizoproksiltenofovirijev fumarat in farmakokinetični ojačevalec (ritonavir ali kobicistat).